Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) EBITDA (2016 - 2025)

Cryo Cell International (CCEL) has disclosed EBITDA for 16 consecutive years, with -$4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 63.91% to -$4.9 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$490803.0, a 183.35% decrease, with the full-year FY2025 number at $436197.0, down 64.1% from a year prior.
  • EBITDA was -$4.9 million for Q4 2025 at Cryo Cell International, down from $1.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.0 million in Q2 2021 to a low of -$6.7 million in Q4 2023.
  • A 5-year average of $100336.6 and a median of $1.2 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 261.46% in 2022, then skyrocketed 54.87% in 2024.
  • Cryo Cell International's EBITDA stood at -$808434.0 in 2021, then tumbled by 261.46% to -$2.9 million in 2022, then plummeted by 128.55% to -$6.7 million in 2023, then surged by 54.87% to -$3.0 million in 2024, then crashed by 63.91% to -$4.9 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's EBITDA are -$4.9 million (Q4 2025), $1.9 million (Q3 2025), and $1.5 million (Q2 2025).